Search Results - "Zolkind, Paul A."

Poor Dental Health as a Risk Factor for Alveolar Ridge Malignancies by Chang, Katherine W., Mazul, Angela L., Lander, Daniel P., Wahle, Benjamin M., Yan, Emily Z., Thorstad, Wade L., Puram, Sidharth V., Jackson, Ryan S., Pipkorn, Patrik, Paniello, Randal C., Zolkind, Paul A., Olshan, Andrew F., Zevallos, Jose P.

“…Objective To determine the association between poor dental health and risk of oral cavity squamous cell cancer (OCSCC) at individual tumor subsites. Study…”
Get full text

The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells by Davitt, Katlin, Babcock, Blake D, Fenelus, Maly, Poon, Chi Kong, Sarkar, Abhishek, Trivigno, Vincent, Zolkind, Paul A, Matthew, Sheena M, Grin'kina, Natalia, Orynbayeva, Zulfiya, Shaikh, Mohammad F, Adler, Victor, Michl, Josef, Sarafraz-Yazdi, Ehsan, Pincus, Matthew R, Bowne, Wilbur B

“…We have developed the anti-cancer peptide, PNC-27, which is a membrane-active peptide that binds to the HDM-2 protein expressed in the cancer cell membranes of…”
Get more information

Abstract PR01: Genomic and functional correlates from a phase II clinical trial of trametinib in surgically resectable oral cavity squamous cell carcinoma by Zolkind, Paul A., Campbell, Katie M., Lin, Tianxiang, Skidmore, Zach, Winkler, Ashley, Barnell, Erica, Giri, Tusar, Adkins, Douglas R., Griffith, Malachi, Dunn, Gavin P., Griffith, Obi L., Uppaluri, Ravindra

“…Abstract Background: Neoadjuvant trametinib treatment of patients with locally advanced oral cavity squamous cell carcinoma (OSCC) demonstrates metabolic- and…”
Get full text

The Rat as a Potential Animal Model for Dysphonia by Zolkind, Paul A., Last, Jordan, Shuminov, Oktay, Silverman, Joshua B., Sundaram, Krishnamurthi, Stewart, Mark, Kollmar, Richard

“…Objectives: Dysphonia, or hoarseness, is the primary complaint of patients with unilateral vocal-fold paralysis due to damage to the recurrent laryngeal nerve…”
Get full text

Abstract 5488: Novel death pathway in a p53 null human leukemia cell line treated with PNC-27 by Fenelus, Maly, Mathew, Sheena M., Zolkind, Paul A., Adler, Victor, Yazdi, Ehsan S., Michl, Josef, Pincus, Matthew R., Bowne, Wilbur B.

“…Abstract Background: PNC-27 is a p53-derived peptide from the human double minute binding domain (HDM-2). This peptide has been shown to induce rapid tumor…”
Get full text